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Efﬁcacy  of  afoxolaner,  a novel  isoxazoline  insecticide/acaricide,  against  Dermacentor  vari-
abilis ticks  was  conﬁrmed  in two  laboratory  studies.  Each  study  utilized  a controlled,
randomized  block  design.  One  day  prior  to  treatment,  beagle  dogs  were  infested  with  50
unfed  adult  ticks.  Repeat  infestations  were  performed  weekly  for  four weeks.  The  number
of live  ticks  remaining  on  each  dog  was  determined  48 h  after  treatment  and  after  each
subsequent  infestation.  A single  oral  treatment  with  a dose  approaching  the minimum
effective  dose  of afoxolaner  (2.5  mg/kg)  eliminated  the  pre-existing  infestations  by  D.  vari-
abilis ticks  and  controlled  weekly  re-infestations  with  99.7–100%  efﬁcacy  up to Day  23  and
>97% efﬁcacy  at  Day  30.
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1. Introduction
Tick control is an important concern for public health
ofﬁcials, pet owners, and veterinarians (Dantas-Torres
et al., 2012; Otranto and Wall, 2008). Indeed, tick infes-
tations can be a nuisance, and heavy tick infestation can
lead to anemia, particularly in young or small dogs. Derma-
centor variabilis, generally known as ‘American dog tick’,
is one of the most common tick species affecting dogs in
the USA (Dryden and Payne, 2004; Goldberg et al., 2002).
D. variabilis is widely distributed across the central and
eastern United States, and also occurs along the Paciﬁc
coast, and it is an important vector of several infectious
agents, including those that cause Rocky Mountain spot-
ted fever, tularemia, and ehrlichiosis in both dogs and
humans (Chomel, 2011; Dantas-Torres et al., 2012; Dryden
and Payne, 2004; Steiert and Gilfoy, 2002). D. variabilis
is also commonly implicated as a cause of tick paralysis
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(Vedanarayanan et al., 2004). Currently, tick control for
dogs is only available in formulations that are topically
applied (Sprays, powders, shampoos, spot ons) or in col-
lars (Beugnet and Franc, 2012). Afoxolaner is a novel
insecticide–acaracide that is administered orally in a chew-
able formulation (Nexgard®, Merial). Afoxolaner is a mem-
ber of the isoxazoline class and works by inhibiting insect
GABA and Glutamate-gated chloride channels (Shoop et al.,
2014), thereby leading to prolonged hyper-excitation and
death of both insects and acarines. This paper describes two
studies that were performed to demonstrate the efﬁcacy of
afoxolaner against D. variabilis ticks.
2. Materials and methods
2.1. Experimental designTwo  similar studies were conducted to demonstrate
the efﬁcacy of afoxolaner against D. variabilis. Both stud-
ies were performed in the USA and were designed in
accordance with standard methods for evaluating the
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Table  1
Study design to evaluate the efﬁcacy of afoxolaner against Dermacentor variabilis.
Study Subject sex Subject age
(months)
Subject body
weight (kg)
Target Treatmenta Challenge
infestations: tick
no.b
Challenge
infestations:
study days
Tick count days
1 6 males, 10
females
6–8 5.7–9.1 Dermacentor
variabilis
Once on Day 0 50 ± 5 −1, 7, 14, 21,
28, 35
2, 9, 16, 23, 30,
37
2  10 males, 6 7–10 5.9–9.6 Dermacentor Once on Day 0 50 ± 5 −1, 7, 14, 21, 2, 9, 16, 23, 30,
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a Treated dogs were given the test medication orally at a minimum dos
b Tick no. = number of ticks used for infestation of each dog on each day
fﬁcacy of parasiticides for the treatment, prevention and
ontrol of tick infestations (Marchiondo et al., 2013). The
tudies were approved by the Merial Institutional Animal
are and Use Committee. Dogs were managed consitent
ith the US Animal Welfare Regulations (USDA, 2008).
.2. Animals
The studies involved 32 purpose bred beagles (16 per
tudy) which were individually identiﬁed by unique ear
attoos. Study 1 included 6 male and 10 female dogs aged
–8 months and weighing 5.7–9.1 kg. Study 2 included 10
ale and 6 female dogs aged 7–10 months and weighing
.9–9.6 kg (Table 1). Studies followed a controlled, random-
zed design. Dogs were in good health and had not been
reated with ectoparasiticides for at least 3 months prior to
reatment. Tick infestations and subsequent counts were
erformed prior to treatment, and conﬁrmed that dogs
ere capable of maintaining adequate infestations. Dogs
ere housed individually. Health observations were con-
ucted daily throughout each study. In addition, hourly
ealth observations were conducted for 4 h following treat-
ent with afoxolaner on Day 0.
.3. Study design
For both studies, seven days prior to treatment (desig-
ated as to Day 0) dogs were infested with 50 adult ticks of
pproximately equivalent sex ratio, which were removed
nd counted 48 h later. The dogs were ranked in order of
hese pre-treatment tick counts (highest to lowest). The
rst two dogs were assigned to Block 1, the next two dogs
o Block 2 and so on until 10 blocks of two dogs each
ere formed. Within blocks, dogs were randomly assigned
o one of two treatment groups. Dogs in Group 1 were
ntreated controls. Dogs in Group 2 were treated once
rally with the appropriate combination of soft chewables
ontaining afoxolaner. Two sizes of chews were used: 0.5 g
nd 1.25 g, containing 11.3 mg  and 28.3 mg  of afoxolaner,
espectively. The soft chewables are not designed to be
ivided, therefore, the dosing was administered as closely
s possible to the minimum effective dose of 2.5 mg/kg
sing whole chews. The doses administered to dogs ranged
rom 2.57 to 3.96 mg/kg body weight in Study 1 and from
.97 to 3.70 mg/kg body weight in Study 2. The dogs were
bserved during the 4 h following their treatment and daily
hroughout the study.
Dogs were infested with 50 adult ticks (25 females and
5 males) on the day prior to treatment (Day – 1) and on
ays 7, 14, 21, and 28. Forty-eight hours after treatment28, 35 37
.5 mg/kg (range 2.57–3.96 mg/kg).
and 48 h after each of the subsequent re-infestations, ticks
were removed and live ticks were counted. These counts
were conducted using a procedure involving methodical
examination of all body areas using ﬁnger tips and/or a
coarse tooth comb to sort through the hair and locate
all ticks following WAAVP guidelines (Marchiondo et al.,
2013). The two  studies used unfed adult D. variabilis
ticks from two separate laboratory-maintained popula-
tions. Each laboratory population had been established
from ticks collected in the USA. Personnel responsible for
collection of animal health and efﬁcacy data were blinded
to the treatment groups.
2.4. Data analysis
Total counts of live ticks were transformed to the nat-
ural logarithm of (count + 1) for calculation of geometric
means by treatment group at each time point. Percent
reduction from the control group mean was calculated for
the treated group at each post-treatment time point using
the formula [(C − T)/C] × 100, where C is the geometric
mean for the control group and T is the geometric mean
for the treated group. The log counts of the treated group
were compared to the log counts of the untreated control
group using an F-test adjusted for the allocation blocks
used to randomize the animals to the treatment groups.
The comparisons were performed using a two-sided test
with a 5% signiﬁcance level.
3. Results
Treated dogs in both studies accepted the afoxolaner
chews based on hourly post-treatment observations for
four hours and daily observations thereafter, and no
vomiting was  reported in treated dogs during either of
the studies. No treatment-related health problems were
observed throughout the studies. At all time-points in both
studies the retention rates of ticks in the untreated con-
trol dogs exceeded the 20% attachment rate recommended
by Marchiondo et al. (2013) to allow a robust comparison
between control and treated groups (Table 2).
In dogs infested one day prior to treatment, afoxolaner
provided 100% curative efﬁcacy against D. variabilis within
48 h following treatment in both studies (Table 2). Dogs
were re-infested on a weekly basis up to Day 28, and
in the two studies the efﬁcacy 48 h after re-infestation
remained at 100% up to Day 16 and >97.3% up to Day
30 (Table 2). There was  a signiﬁcant difference (p < 0.001)
between treated and control dogs for counts of ticks at all
time-points up to Day 30.
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Table 2
Geometric mean and range of live Dermacentor variabilis tick counts on control dogs 48 h after treatment (Day – 1 infestation) or after subsequent re-
infestations, and percent efﬁcacy based on geometric means.
Day of
infestation
Day of tick
count
Study 1
Geometric mean counts
in control dogs (range)
Study 1
Percent efﬁcacy based
on geometric meansa
Study 2
Geometric mean counts
in  control dogs (range)
Study 2
Percent efﬁcacy based
on geometric meansa
−1 2 40.1 (32–52) 100 40.0 (27–50) 100
7  9 40.3 (33–50) 100 29.1 (15–50) 100
14  16 33.3 (27–47) 100 26.2 (14–47) 100
7 
3 
reated a
USDA, 2008. Animal Welfare Regulations, 9CFR. http://awic.nal.usda.21  23 33.9 (24–43) 99.
28  30 29.3 (17–47) 97.
a There was  a signiﬁcant difference (p < 0.001) in tick counts between t
4. Discussion
Afoxolaner was highly effective in eliminating existing
infestations of D. variabilis, demonstrating 100% effec-
tiveness within 48 h following a single oral treatment.
Afoxolaner also provided extended efﬁcacy following re-
infestation with D. variabilis ticks, with >97.3% efﬁcacy
for one month after treatment. The excellent efﬁcacy of
afoxolaner against D. variabilis for an entire month after
treatment is predicted by the plasma concentration proﬁle
of afoxolaner, which remains above the EC90 for D. variabilis
(afoxolaner plasma concentration at which there is 90%
effectiveness) past 30 days after administration of the min-
imum dose of 2.5 mg/kg body weight (Letendre et al., 2014).
There is no direct comparison with other acaricidal
treatment, but it is possible to look at the published results
of tick efﬁcacy studies using a comparable design. The aca-
ricidal effect of afoxolaner in the two studies presented
here was close to that of topical products reported in the
literature. Rugg et al. (2007) reported two studies evaluat-
ing efﬁcacy of topical products against D. variabilis. In one
of these studies the efﬁcacy of a topical product contain-
ing metaﬂumizone + amitraz against D. variabilis ticks 48 h
after infestation was 89.4% on Day 28 (Rugg et al., 2007).
The second study evaluated the efﬁcacy of a topical prod-
uct containing metaﬂumizone + amitraz as well as a topical
product containing ﬁpronil + S-methoprene against D. vari-
abilis ticks 48 h after infestation and reported efﬁcacy of
89.8 and 93.8% respectively at Day 28 (Rugg et al., 2007).
This is the ﬁrst time that an oral formulation provides a
month long efﬁcacy against tick that is comparable to aca-
ricidal spot-on products.
Pet owners may  prefer the option of treating their dog
with an oral medication that provides both ﬂea and tick
control compared to a topical application. The efﬁcacy
of some topical products may  be affected by bathing or
swimming, or there may  be a period of time in which the
application site should be avoided by pet owners (Blagburn
and Dryden, 2009).
Nexgard® (afoxolaner) is currently the only oral product
that kills adult ﬂeas and treats several tick species including
the American dog tick.
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